© peterschreiber. media - stock.adoCancer immunotherapies can save lives, yet their side effect — cytokine release syndrome (CRS) — remains a barrier for wider use, even though IL 6 receptor antagonists can treat it. Now the UK company Poolbeg Pharma plc, together with Johnson & Johnson, investigates how CRS might be prevented. The programme is backed by a £3.4m grant from the MRC.
Tag Archive for: cancer immune therapy
Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.
,